Determined Transglutaminase 1 Activity in Blood Serum for Brain Cancer Patients and Healthy People

Cancer is defined as a group of abnormal cells that grow and spread unusually, and sometimes their proliferation cannot be controlled. These tumours are usually called cancer. Cancer may affect damaged parts of the body, including the brain. This study focused on the activity of transglutaminase 1 enzyme in the blood serum of brain cancer patients and then compared it with the control group. The study also included the effect of age, gender, body mass index, and glucose on the transglutaminase 1 enzyme in the blood serum of patients with brain cancer. The study sample consisted of 45 samples of brain cancer patients, (45) samples as a control group. The results of this study showed a significant decrease in the activity of transglutaminase 1 in brain cancer patients (902.66 ± 14.27 ng/L) compared to the control group (1594.66 ± 32.95 ng/L). Gender and age also impact the enzyme; in the control group only, males had lower enzyme activity than females, and the enzyme's activity decreased with age in both groups (brain cancer patients and controls). The findings also demonstrate that there was a discernible difference in the serum glucose concentration of brain cancer patients when compared to the control group, although it was still within normal allowable limits, and that there was a decrease in the enzyme's activity with an increase in body mass index values in both the patient and control groups. The investigation of transglutaminase 1 is a useful marker for identifying brain cancer and can be utilized in early diagnosis.